Latest Conference Articles

November 6th 2015, 1:44pm

PER® Chemotherapy Foundation Symposium (CFS)

Adding the MEK inhibitor trametinib to the BRAF inhibitor dabrafenib significantly improves long-term outcomes while lowering certain adverse events associated with either agent alone for patients with BRAF-mutated metastatic melanoma.

November 6th 2015, 12:55pm

LUGPA Annual Meeting

E. David Crawford, MD, discussed issues with FDA standards for ADT agents and current treatment approaches to androgen deprivation in prostate cancer at the 2015 LUGPA Annual Meeting.

November 6th 2015, 12:19pm

PER® Chemotherapy Foundation Symposium (CFS)

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program and Head of Experimental Therapeutics, NYU Langone Medical Center, discusses the significance of the FDA approval of the combination of dabrafenib and trametinib for patients with unresectable or metastatic melanoma who harbor a BRAF V600E or V600K mutation.

November 6th 2015, 10:43am

PER® Chemotherapy Foundation Symposium (CFS)

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses emerging therapies for patients with triple-negative breast cancer.

November 6th 2015, 6:33am

PER® Chemotherapy Foundation Symposium (CFS)

Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.

November 6th 2015, 6:06am

LUGPA Annual Meeting

Evan R. Goldfischer, MD, MBA, FACS, director of the Research Department at Premier Medical Group of the Hudson Valley, discusses the benefits of integrated medical groups.

November 5th 2015, 2:30pm

PER® Chemotherapy Foundation Symposium (CFS)

The kinase inhibitors sorafenib and lenvatinib have significantly altered the treatment paradigm for patients with advanced radioactive iodine-refractory differentiated thyroid cancer in both older and younger populations.

November 5th 2015, 2:04pm

PER® Chemotherapy Foundation Symposium (CFS)

Patrick I. Borgen, MD, chair, Department of Surgery, head, Brooklyn Cancer Center, Maimonides Medical Center, compares the efficacy of surgical versus medical treatment of patients with breast cancer.

November 5th 2015, 1:47pm

PER® Chemotherapy Foundation Symposium (CFS)

While the prognosis remains good for individuals with HPV-positive oropharyngeal cancers, the incidence of these cancers continues to rise, and researchers are currently seeking less intense treatment options that are equally effective but not as toxic for patients.

November 5th 2015, 12:58pm

PER® Chemotherapy Foundation Symposium (CFS)

The use of neoadjuvant chemotherapy in advanced ovarian cancer continues to increase, even though the practice has not been shown to improve survival versus primary cytoreduction.

November 5th 2015, 12:47pm

PER® Chemotherapy Foundation Symposium (CFS)

Franco Muggia, MD, professor of Medicine, NYU Langone Medical Center, discusses the current status of intraperitoneal therapy for patients with gynecologic malignancies.

November 5th 2015, 12:32pm

PER® Chemotherapy Foundation Symposium (CFS)

Early promising responses seen with immune checkpoint inhibitors for patients with ovarian cancer still need to be validated in larger randomized trials before a conclusion is made regarding their true efficacy.

November 4th 2015, 2:42pm

PER® Chemotherapy Foundation Symposium (CFS)

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the efficacy of regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

November 4th 2015, 2:12pm

PER® Chemotherapy Foundation Symposium (CFS)

Monoclonal antibodies are poised to revolutionize the treatment of adult patients with relapsed acute lymphoblastic leukemia, specifically blinatumomab and inotuzumab ozogamicin.

November 4th 2015, 1:59pm

PER® Chemotherapy Foundation Symposium (CFS)

Optimizing outcomes with novel antibodies in multiple myeloma will involve combination regimens with established agents.

November 4th 2015, 1:31pm

PER® Chemotherapy Foundation Symposium (CFS)

The landscape for the diagnosis and treatment of polycythemia vera (PV) is changing, and that's good news for patients and practitioners who can look to improvements ahead.

November 4th 2015, 12:52pm

PER® Chemotherapy Foundation Symposium (CFS)

C. Ola Landgren, MD, PhD, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses minimal residual disease detection for progression-free survival and overall survival for patients with multiple myeloma.

November 4th 2015, 12:39pm

PER® Chemotherapy Foundation Symposium (CFS)

B-cell pathway inhibitors have shown impressive survival benefits for patients with chronic lymphocytic leukemia, but require careful monitoring and possible suspension to control adverse events.

November 4th 2015, 6:00am

LUGPA Annual Meeting

Independent urology practices are at a crossroads as they face substantial Medicare payment change, shifts in physician employment and autonomy, and cutting edge developments in clinical care.

October 27th 2015, 2:12pm

International Thyroid Congress

John Copland, PhD, faculty member in the department of cancer biology, Mayo Clinic, explains his research on patient-derived xenograft (PDX) models in anaplastic thyroid cancer.